-
Retatrutide
— INCRETIN RECEPTOR RESEARCH, 20mg / Vial, listed purity 99.8% (batch COA pending), £228.00
Triple incretin-family receptor agonist studied in vitro.
-
Tirzepatide
— DUAL AGONIST, 30mg / Vial, listed purity 99.8% (batch COA pending), £228.00
Dual incretin (GIP) receptor agonist studied in vitro.
-
Semaglutide
— INCRETIN RECEPTOR RESEARCH, 10mg / Vial, listed purity 99.8% (batch COA pending), £77.00
Incretin receptor agonist studied in vitro.
-
Cagrilintide
— AMYLIN ANALOGUE, 5mg / Vial, listed purity 99.7% (batch COA pending), £160.00
Long-acting amylin analogue studied in vitro.
-
AOD-9604
— METABOLIC, 5mg / Vial, listed purity 99.3% (batch COA pending), £58.00
Modified GH fragment 177-191 studied in vitro.
-
CJC-1295 (no DAC)
— GH SECRETAGOGUE, 10mg / Vial, listed purity 99.7% (batch COA pending), £66.00
Modified GRF 1-29 (no DAC). GH secretagogue research.
-
CJC-1295 with DAC
— GH SECRETAGOGUE, 5mg / Vial, listed purity 99.7% (batch COA pending), £67.00
CJC-1295 with DAC. Extended half-life GH secretagogue research.
-
CJC-1295 / Ipamorelin
— GH SECRETAGOGUE, 5 + 5mg / Vial, listed purity 99.6% (batch COA pending), £62.00
GH secretagogue synergy blend — CJC-1295 and Ipamorelin.
-
GHRP-2
— GH SECRETAGOGUE, 10mg / Vial, listed purity 99.6% (batch COA pending), £63.00
Growth hormone releasing peptide-2. GH secretagogue research.
-
GHRP-6
— GH SECRETAGOGUE, 10mg / Vial, listed purity 99.6% (batch COA pending), £63.00
Growth hormone releasing peptide-6 studied in vitro.
-
IGF-1 LR3
— GROWTH FACTOR, 1mg / Vial, listed purity 99.5% (batch COA pending), £77.00
Long R3 insulin-like growth factor-1. Cellular growth research.
-
Ipamorelin
— GH SECRETAGOGUE, 10mg / Vial, listed purity 99.7% (batch COA pending), £49.00
Pentapeptide GH secretagogue. Selective GH release research.
-
MOTS-C
— MITOCHONDRIAL, 10mg / Vial, listed purity 99.6% (batch COA pending), £45.00
Mitochondrial-derived peptide. Metabolic regulation research.
-
Retatrutide
— INCRETIN RECEPTOR RESEARCH, 10mg / Vial, listed purity 99.8% (batch COA pending), £90.00
Triple incretin-family receptor agonist studied in vitro.
-
Retatrutide
— INCRETIN RECEPTOR RESEARCH, 30mg / Vial, listed purity 99.8% (batch COA pending), £302.00
Triple incretin-family receptor agonist studied in vitro.
-
Retatrutide
— INCRETIN RECEPTOR RESEARCH, 60mg / Vial, listed purity 99.8% (batch COA pending), £416.00
Triple incretin-family receptor agonist studied in vitro.
-
Semaglutide
— INCRETIN RECEPTOR RESEARCH, 5mg / Vial, listed purity 99.8% (batch COA pending), £103.00
Incretin receptor agonist studied in vitro.
-
Sermorelin
— GH SECRETAGOGUE, 10mg / Vial, listed purity 99.6% (batch COA pending), £67.00
GHRH(1-29) analogue. GH secretagogue research.
-
Tesamorelin
— GH SECRETAGOGUE, 10mg / Vial, listed purity 99.6% (batch COA pending), £71.00
GHRH analogue studied in vitro.
-
Tesamorelin / Ipamorelin
— GH SECRETAGOGUE, 12 + 6mg / Vial, listed purity 99.6% (batch COA pending), £86.00
GH-axis blend — Tesamorelin and Ipamorelin.
-
Tirzepatide
— DUAL AGONIST, 10mg / Vial, listed purity 99.8% (batch COA pending), £58.00
Dual incretin (GIP) receptor agonist studied in vitro.
-
Tirzepatide
— DUAL AGONIST, 60mg / Vial, listed purity 99.8% (batch COA pending), £342.00
Dual incretin (GIP) receptor agonist studied in vitro.
-
Tirzepatide / Ipamorelin Blend
— METABOLIC BLEND, 12 + 6mg / Vial, listed purity 99.7% (batch COA pending), £125.00
Metabolic + GH blend — Tirzepatide and Ipamorelin.